INTRODUCTION
Autoimmune hepatitis (AIH) is a generally progressive, chronic disease with occasionally fluctuating activity that occurs worldwide in children and adults. 1 Although the cause of AIH is unknown, aberrant autoreactivity is thought to play a role in its pathogenesis. 2 AIH has been reported in patients with various diseases, including type 1 diabetes, thyroiditis, glomerulonephritis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, and ulcerative colitis. [3] [4] [5] However, systemic connective tissue diseases, such as systemic lupus erythematosus, undifferentiated connective tissue disease, mixed connective tissue disease, and systemic sclerosis (SSc), have been reported infrequently in association with AIH. 6 Here, we report a patient presenting with liver cirrhosis due to AIH combined with SSc, and present a review of the relevant literature.
CASE REPORT
A 51-year-old woman visited our hospital with hematemesis. She had no other relevant medical history and no alcohol consumption and not been taking any medication. The patient's blood pressure was 100/60 mmHg and her pulse was and a moderate amount of ascites. We performed paracentesis and serum ascites albumin gradient was 2.5.
Endoscopy showed grade 4 varices (F3), and a small ulcer was detected in one of the varices, which was suggestive of hemorrhage. We performed band ligation of the esophageal varices. We could not find other cause of portal hypertension.
Liver biopsy showed partial expansion with lymphoplasmacytic infiltration, bridging fibrosis, and multifocal drop out of hepatocytes, replaced by lymphoid cells in the lobules, suggesting chronic active hepatitis (Fig. 2) . These histological and clinical findings were consistent with AIH. The
International Autoimmune Hepatitis Group score was 18.
Additionally, the patient had suffered from Raynaud's syndrome, sclerodactyly, arthralgia, and fatigue for 3 years prior 
DISCUSSION
SSc is a chronic systemic disease that affects the skin, lungs, heart, gastrointestinal tract, kidneys, and musculoskeletal system. The disorder is characterized by three features: tissue fibrosis, vessel vasculopathy, and an autoimmune response associated with specific autoantibodies. 7 Although up to 90% of patients with SSc have been estimated to have gastrointestinal involvement, 8 liver disease has been reported only rarely in these cases. In a review of 727 patients with scleroderma, only eight (1.1%) had hepatic involvement. 9 Primary biliary cirrhosis (PBC) is the most frequently encountered liver disease in SSc patients. In a series of 83 patients with primary biliary cirrhosis, 17% of patients had concomitant SSc. 10 The pathological mechanisms of AIH in patients with SSc remain unclear. However, AIH may be due, in part, to dysfunction of both cellular and humoral immunity related to SSc, as anti-centromere antibody has been detected in up to 13% of patients with AIH. [11] [12] [13] There have been only two reports in the literature regarding investigations related to anti-centromere antibodies in patients with AIH, which indicated the presence of these antibodies at a low frequency of 3% in cases of AIH. 14, 15 In the Japanese population, the frequency of the discrete speckled pattern of FANA (closely associated with anti-centromere antibody) is increased in AIH patients with anti-centromere antibody, supporting the close association between the AIH and SSc.
However, no definite conclusions can be drawn from these findings, and further studies are necessary to examine the relationship between anti-centromere antibody and AIH.
The diagnosis of AIH in this case was reasonable because CREST, calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia syndrome; CRST, calcinosis cutis, Raynaud's phenomenon, sclerodactyly, telangiectasia syndrome; Raynaud's, Raynaud's phenomenon; F, female; FANA, fluorescent anti-nuclear antibody; Anti-centromere, anti-centromere antibody; PDL, prednisolone; SSc, systemic sclerosis.
the patient with SSc fulfilled all the diagnostic criteria of the International Autoimmune Hepatitis Group for AIH: 16 1) increased AST and ALT levels with ALP levels less than three times the normal value; 2) total γ-globulin or IgG levels more than 1. (Table 2 ).
Among them, three cases were diagnosed with SSc 1 month to 7 years before developing AIH, and in the remaining one case, SSc and AIH were diagnosed together. This case also had SSc and AIH together at the time of initial diagnosis.
These results indicate that patients with SSc may be at in- 17 However, in all five cases after high dose prednisolone (30-40 mg), symptoms were improved and the outcome of AIH was favorable. However, further studies in larger numbers of cases are required to determine the treatment outcome of combined AIH and SSc.
The combination of SSc and AIH in the early phase may be overlooked if not examined by a specialist in rheumatology.
The symptoms may appear gradually during the clinical course, and therefore it is important to consider the combination of SSc and AIH even in cases with a confirmed diagnosis of either disease entity. The results of the present case indicate that it is necessary to consider the possibility of AIH even-in patients with limited SSc presenting with skin manifestations, such as Raynaud's phenomenon and sclerodactyly.
In conclusion, patients with either AIH or SSc should be monitored for further development of concurrent autoimmune disease. The early diagnosis of AIH combined with SSc will be helpful in achieving optimal management in such cases.
